

ACSAP 2020 Book 1 (*Cardiology Care*)

Release date: March 16, 2020

BCACP test deadline: 11:59 p.m. (Central) on September 15, 2020.

ACPE test deadline: 11:59 p.m. (Central) on March 16, 2023.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

ACSAP Target Audience: The target audience for ACSAP 2020 Book 1 (*Cardiology Care*) is board-certified and advanced-level ambulatory care pharmacists who manage patients with complex cardiovascular diseases.

Module I (4.5 CPE) Cardiology Care I 0217-9999-20-005-H01-P

Chapter: Aspirin for Primary Prevention of CVD

Learning Objectives

1. Evaluate atherosclerotic cardiovascular disease (ASCVD) risk factors and tools to estimate short- and long-term ASCVD outcomes in various patient populations.
2. Analyze the benefit-risk of aspirin for the primary prevention of ASCVD.
3. Evaluate evidence-based literature to assess appropriate aspirin use for the primary prevention of ASCVD.
4. Using recommendations from various clinical practice guidelines, justify the use of aspirin for the primary prevention of ASCVD.

Chapter: Antiplatelet Therapy for Secondary Prevention of Cardiovascular Disease

Learning Objectives

1. Evaluate antiplatelet therapy in the secondary prevention of stroke, acute coronary syndrome (ACS), and stable ischemic heart disease (IHD).
2. Analyze the benefit-risk of antiplatelet therapy in the secondary prevention of stroke, ACS, and stable IHD.
3. Evaluate the evidence for antiplatelet therapy in the secondary prevention of stroke, ACS, and stable IHD.
4. Design an evidence-based antiplatelet therapy regimen in the secondary prevention of stroke, ACS, and stable IHD.

Module II (4.5 CPE) Cardiology Care II 0217-9999-20-006-H01-P

Chapter: Perioperative Management of Anticoagulation/Antiplatelets

Learning Objectives

1. Evaluate data from clinical studies and apply them to perioperative management of anticoagulation.
2. Assess guideline recommendations for optimal perioperative management of anticoagulation and antiplatelets.
3. Evaluate a patient's perioperative risk of thromboembolism and bleeding.
4. Design an appropriate treatment plan for perioperative treatment of a patient taking an anticoagulant or antiplatelet.

Chapter: VTE Prophylaxis in Patients with Obesity

Learning Objectives

1. Apply the results from various venous thromboembolism (VTE) and bleeding risk assessment tools to the care of the patient with obesity.
2. Evaluate thromboprophylactic recommendations of clinical practice guidelines as they apply to the care of the patient with obesity.
3. Assess differences in pharmacologic agents used for primary venous thromboprophylaxis in the patient with obesity.
4. Develop a VTE prophylactic regimen for the patient with obesity.

Module III (4.0 CPE) Cardiology Care III 0217-9999-20-007-H01-P

Chapter: Peripheral Artery Disease

Learning Objectives

1. Assess risk factors for peripheral arterial disease (PAD) as they relate to the prognosis and goals of treatment.
2. Evaluate the results of diagnostic testing for PAD.
3. Develop a treatment plan to address cardiovascular risk reduction in a patient with PAD.
4. Distinguish between the approaches to symptomatic management of PAD.
5. Justify pharmacist involvement in comprehensive medication management for patients with PAD.

Chapter: CV Services in the Community Setting

Learning Objectives

1. Assess quality measures and reimbursement opportunities necessary to demonstrate the value of pharmacy services in community pharmacy practice settings.
2. Apply tools and resources to identify patients in a community pharmacy setting at high-risk for CVD and to create a plan to monitor and manage cardiovascular risk factors.
3. Analyze challenges and opportunities for community-based medication management services in the management and prevention of CVD.
4. Evaluate the impact of health information technology in sustaining cardiovascular pharmacy services.
5. Design outcome measure targets for evaluating quality performance.

Module IV (4.5 CPE) Cardiology Care IV 0217-9999-20-008-H01-P

Interactive Case: Treatment-Resistant Hypertension

Learning Objectives

1. Distinguish between treatment-resistant hypertension (TRH), secondary hypertension, refractory hypertension, and pseudo-resistance.
2. Evaluate causes of TRH.
3. Construct an appropriate plan for evaluating TRH, including blood pressure monitoring, physical examination, and laboratory evaluation.
4. Develop evidence-based individualized treatment strategies for managing TRH.

Interactive Case: Dyslipidemia

Learning Objectives

1. Evaluate the patient with dyslipidemia in order to determine when and which pharmacological therapy is indicated.
2. Compare and contrast the different dyslipidemia recommendations by medical organizations.
3. Justify the role of statin and non-statin therapy in the management of primary and secondary prevention of cardiovascular disease.
4. Design a patient-specific dyslipidemia regimen.

Interactive Case: Chronic Heart Failure

Learning Objectives

1. Assess for medical conditions and other confounders influencing the clinical interpretation of BNP
2. Compare and contrast therapies for heart failure with reduced ejection fraction and heart failure with preserved ejection fraction
3. Evaluate the impact of specific interventions on heart failure morbidity and mortality
4. Design evidence-based pharmacotherapy to improve heart failure related outcomes